Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion

• Status: Completed
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Monthly intravitreal ranibizumab (IVR) during the first 6 month had great effect for macular edema with branch retinal vein occlusion (BVO) both in visual and anatomical outcome. It is expected that similar results could be obtained by less frequent IVR. The purpose of this study is to investigate if IVR by PRN is as effective as by monthly. In addition, the investigators are going to study the relationship between macular edema and the size and location of retinal non-perfusion area.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nagoya City University
• Collaborator: Novartis
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Signed informed consent form

• Macula edema secondary to BRVO

• BCVA of 77 to 20 letters assessed with the use of ETDRS charts

• CRT ≧250μm

Exclusion Criteria:

• Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye)

• History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO

• Ocular disorders in the study eye that may confound interpretation of study results

• BCVA over 77 letters between screening and Day 0

• The pregnant or lactating woman